SETX

Across TCGA pan-cancer cohorts, SETX mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of SETX’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where SETX mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types SETX is over-expressed in tumor, although a few such as COAD and PDAC show the opposite, repressed pattern.

HNSC, COAD, and PDAC are the cancer types where SETX tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SETX mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	Male	All	+0.177	<.001	8	view →
COAD	All	All	−0.510	<.001	6	view →
PDAC	All	II,III,IV	−0.165	.011	4	view →
LSCC	All	II,III,IV	+0.112	.001	4	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

SETX–HNSC

Open the HNSC breakdown →